Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.
Heather L GardnerKarthigayini SivaprakasamNatalia BrionesVictoria ZismannNieves PerdigonesKevin DrennerSalvatore FacistaRyan RichholtWinnie LiangJessica AldrichJeffrey M TrentPeter G ShieldsNicholas RobinsonJeremy JohnsonSusan LanaPeter HoughtonJoelle FengerGwendolen LorchKatherine A JanewayCheryl A LondonWilliam P D HendricksPublished in: Communications biology (2019)
Osteosarcoma (OS) is a rare, metastatic, human adolescent cancer that also occurs in pet dogs. To define the genomic underpinnings of canine OS, we performed multi-platform analysis of OS tumors from 59 dogs, including whole genome sequencing (n = 24) and whole exome sequencing (WES; n = 13) of primary tumors and matched normal tissue, WES (n = 10) of matched primary/metastatic/normal samples and RNA sequencing (n = 54) of primary tumors. We found that canine OS recapitulates features of human OS including low point mutation burden (median 1.98 per Mb) with a trend towards higher burden in metastases, high structural complexity, frequent TP53 (71%), PI3K pathway (37%), and MAPK pathway mutations (17%), and low expression of immune-associated genes. We also identified novel features of canine OS including putatively inactivating somatic SETD2 (42%) and DMD (50%) aberrations. These findings set the stage for understanding OS development in dogs and humans, and establish genomic contexts for future comparative analyses.
Keyphrases
- copy number
- genome wide
- endothelial cells
- squamous cell carcinoma
- small cell lung cancer
- dna methylation
- single cell
- duchenne muscular dystrophy
- poor prognosis
- computed tomography
- young adults
- induced pluripotent stem cells
- mental health
- high throughput
- long non coding rna
- cell proliferation
- papillary thyroid
- lymph node metastasis